RR

Rajashree Rakesh Gandhi

Active Director Additional Director DIN 10577679
DIN 10577679 First appointment Apr 2024 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Rajashree Rakesh Gandhi

Data last updated:

Rajashree Rakesh Gandhi is an Additional Director at Alephata Institute Of Medical Sciences Private Limited (since 2024). The company operates in Healthcare.

DIN 10577679
Primary Designation Additional Director
Industry Healthcare
First Appointment 04 Apr 2024
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director04 Apr 20242023Active

Board colleagues of Rajashree Rakesh Gandhi

Directorship timeline

Open interactive timeline →
Alephata Institute Of Medical Sciences Private Limited
Premium access

Shareholding and investment profile for Rajashree Rakesh Gandhi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajashree Rakesh Gandhi

Rajashree Rakesh Gandhi currently holds 1 directorship: Alephata Institute Of Medical Sciences Private Limited (Additional Director, since 04 Apr 2024).

Rajashree Rakesh Gandhi was first appointed on 04 Apr 2024 as Additional Director at Alephata Institute Of Medical Sciences Private Limited.

The current boards of Rajashree Rakesh Gandhi's companies include Rakesh Gandhi Kantilal (Alephata Institute Of Medical Sciences Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available